Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer

Shao Wen Hung, Ching Feng Chiu, Tai An Chen, Chiao Li Chu, Chi Chang Huang, Lie Fen Shyur, Chi Ming Liang, Shu Mei Liang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Breast cancer is one of the most common cancers in women worldwide and metastasis is the major cause of breast cancer death. Development of new therapeutic agents for inhibiting breast cancer metastasis is therefore an urgent need. We previously demonstrated that recombinant DNA-derived viral capsid protein VP1 (rVP1) of foot-and-mouth disease virus-induced apoptosis of MCF-7 breast cancer cells in vitro. Here, we investigated whether rVP1 exhibits any inhibitory effects on migration/metastasis and human epidermal growth factor receptor 2 (HER-2), a well-known biomarker for poor prognosis of breast cancer. The effects of rVP1 on cancer cell migration/invasion and metastasis were evaluated using Transwell migration assay and animal cancer models of metastasis. Western blotting, RT-PCR, flow cytometry, immunohistochemistry, and immunofluorescence staining techniques were used to investigate the effects of rVP1 on HER-2 and signal transduction mediators. Non-cytotoxic concentrations of rVP1-induced mesenchymal-epithelial transition and significantly suppressed AP-2α and HER-2 expression as well as the migration and invasion of a variety of breast cancer cell lines in a β1-integrin-dependent manner in vitro. Gross and histopathologic examinations showed that rVP1 also suppressed metastasis of several breast cancer cell lines, including HER-2-overexpressing SK-BR-3 and BT-474 cells to lung, liver, or peripheral lymph node in orthotopic allograft/xenograft murine models. In addition, rVP1 significantly prolonged survival in breast cancer-bearing mice. Notably, no apparent side effects of rVP1 were detected, as shown by normal complete blood count levels and serum biochemistry profiles, including AST, ALT, BUN, and creatine. This study demonstrates that rVP1 suppresses the migration, invasion, and metastasis of breast cancer cells via binding to β1 integrin receptor and down-regulation of AP-2α and HER-2 expression. The effectiveness of rVP1 on inhibiting migration/metastasis of breast cancer and HER-2 expression suggests that it may be suitable for serving as potential therapeutics for metastatic breast cancer particularly HER-2-overexpressing cancer.

Original languageEnglish
Pages (from-to)89-105
Number of pages17
JournalBreast Cancer Research and Treatment
Volume136
Issue number1
DOIs
Publication statusPublished - Nov 1 2012
Externally publishedYes

Fingerprint

Viral Proteins
Recombinant Proteins
Breast Neoplasms
Neoplasm Metastasis
Integrins
Neoplasms
human ERBB2 protein
Foot-and-Mouth Disease Virus
Cell Line
Epithelial-Mesenchymal Transition
Recombinant DNA
Blood Cell Count
Creatine
Blood Urea Nitrogen
Capsid Proteins
Heterografts
Biochemistry
Cell Movement
Fluorescent Antibody Technique
Allografts

Keywords

  • Breast cancer
  • HER-2
  • Metastasis
  • Migration
  • rVP1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer. / Hung, Shao Wen; Chiu, Ching Feng; Chen, Tai An; Chu, Chiao Li; Huang, Chi Chang; Shyur, Lie Fen; Liang, Chi Ming; Liang, Shu Mei.

In: Breast Cancer Research and Treatment, Vol. 136, No. 1, 01.11.2012, p. 89-105.

Research output: Contribution to journalArticle

Hung, Shao Wen ; Chiu, Ching Feng ; Chen, Tai An ; Chu, Chiao Li ; Huang, Chi Chang ; Shyur, Lie Fen ; Liang, Chi Ming ; Liang, Shu Mei. / Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 1. pp. 89-105.
@article{74748cbe617142d4a55b5d489a9c1059,
title = "Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer",
abstract = "Breast cancer is one of the most common cancers in women worldwide and metastasis is the major cause of breast cancer death. Development of new therapeutic agents for inhibiting breast cancer metastasis is therefore an urgent need. We previously demonstrated that recombinant DNA-derived viral capsid protein VP1 (rVP1) of foot-and-mouth disease virus-induced apoptosis of MCF-7 breast cancer cells in vitro. Here, we investigated whether rVP1 exhibits any inhibitory effects on migration/metastasis and human epidermal growth factor receptor 2 (HER-2), a well-known biomarker for poor prognosis of breast cancer. The effects of rVP1 on cancer cell migration/invasion and metastasis were evaluated using Transwell migration assay and animal cancer models of metastasis. Western blotting, RT-PCR, flow cytometry, immunohistochemistry, and immunofluorescence staining techniques were used to investigate the effects of rVP1 on HER-2 and signal transduction mediators. Non-cytotoxic concentrations of rVP1-induced mesenchymal-epithelial transition and significantly suppressed AP-2α and HER-2 expression as well as the migration and invasion of a variety of breast cancer cell lines in a β1-integrin-dependent manner in vitro. Gross and histopathologic examinations showed that rVP1 also suppressed metastasis of several breast cancer cell lines, including HER-2-overexpressing SK-BR-3 and BT-474 cells to lung, liver, or peripheral lymph node in orthotopic allograft/xenograft murine models. In addition, rVP1 significantly prolonged survival in breast cancer-bearing mice. Notably, no apparent side effects of rVP1 were detected, as shown by normal complete blood count levels and serum biochemistry profiles, including AST, ALT, BUN, and creatine. This study demonstrates that rVP1 suppresses the migration, invasion, and metastasis of breast cancer cells via binding to β1 integrin receptor and down-regulation of AP-2α and HER-2 expression. The effectiveness of rVP1 on inhibiting migration/metastasis of breast cancer and HER-2 expression suggests that it may be suitable for serving as potential therapeutics for metastatic breast cancer particularly HER-2-overexpressing cancer.",
keywords = "Breast cancer, HER-2, Metastasis, Migration, rVP1",
author = "Hung, {Shao Wen} and Chiu, {Ching Feng} and Chen, {Tai An} and Chu, {Chiao Li} and Huang, {Chi Chang} and Shyur, {Lie Fen} and Liang, {Chi Ming} and Liang, {Shu Mei}",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s10549-012-2238-7",
language = "English",
volume = "136",
pages = "89--105",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer

AU - Hung, Shao Wen

AU - Chiu, Ching Feng

AU - Chen, Tai An

AU - Chu, Chiao Li

AU - Huang, Chi Chang

AU - Shyur, Lie Fen

AU - Liang, Chi Ming

AU - Liang, Shu Mei

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Breast cancer is one of the most common cancers in women worldwide and metastasis is the major cause of breast cancer death. Development of new therapeutic agents for inhibiting breast cancer metastasis is therefore an urgent need. We previously demonstrated that recombinant DNA-derived viral capsid protein VP1 (rVP1) of foot-and-mouth disease virus-induced apoptosis of MCF-7 breast cancer cells in vitro. Here, we investigated whether rVP1 exhibits any inhibitory effects on migration/metastasis and human epidermal growth factor receptor 2 (HER-2), a well-known biomarker for poor prognosis of breast cancer. The effects of rVP1 on cancer cell migration/invasion and metastasis were evaluated using Transwell migration assay and animal cancer models of metastasis. Western blotting, RT-PCR, flow cytometry, immunohistochemistry, and immunofluorescence staining techniques were used to investigate the effects of rVP1 on HER-2 and signal transduction mediators. Non-cytotoxic concentrations of rVP1-induced mesenchymal-epithelial transition and significantly suppressed AP-2α and HER-2 expression as well as the migration and invasion of a variety of breast cancer cell lines in a β1-integrin-dependent manner in vitro. Gross and histopathologic examinations showed that rVP1 also suppressed metastasis of several breast cancer cell lines, including HER-2-overexpressing SK-BR-3 and BT-474 cells to lung, liver, or peripheral lymph node in orthotopic allograft/xenograft murine models. In addition, rVP1 significantly prolonged survival in breast cancer-bearing mice. Notably, no apparent side effects of rVP1 were detected, as shown by normal complete blood count levels and serum biochemistry profiles, including AST, ALT, BUN, and creatine. This study demonstrates that rVP1 suppresses the migration, invasion, and metastasis of breast cancer cells via binding to β1 integrin receptor and down-regulation of AP-2α and HER-2 expression. The effectiveness of rVP1 on inhibiting migration/metastasis of breast cancer and HER-2 expression suggests that it may be suitable for serving as potential therapeutics for metastatic breast cancer particularly HER-2-overexpressing cancer.

AB - Breast cancer is one of the most common cancers in women worldwide and metastasis is the major cause of breast cancer death. Development of new therapeutic agents for inhibiting breast cancer metastasis is therefore an urgent need. We previously demonstrated that recombinant DNA-derived viral capsid protein VP1 (rVP1) of foot-and-mouth disease virus-induced apoptosis of MCF-7 breast cancer cells in vitro. Here, we investigated whether rVP1 exhibits any inhibitory effects on migration/metastasis and human epidermal growth factor receptor 2 (HER-2), a well-known biomarker for poor prognosis of breast cancer. The effects of rVP1 on cancer cell migration/invasion and metastasis were evaluated using Transwell migration assay and animal cancer models of metastasis. Western blotting, RT-PCR, flow cytometry, immunohistochemistry, and immunofluorescence staining techniques were used to investigate the effects of rVP1 on HER-2 and signal transduction mediators. Non-cytotoxic concentrations of rVP1-induced mesenchymal-epithelial transition and significantly suppressed AP-2α and HER-2 expression as well as the migration and invasion of a variety of breast cancer cell lines in a β1-integrin-dependent manner in vitro. Gross and histopathologic examinations showed that rVP1 also suppressed metastasis of several breast cancer cell lines, including HER-2-overexpressing SK-BR-3 and BT-474 cells to lung, liver, or peripheral lymph node in orthotopic allograft/xenograft murine models. In addition, rVP1 significantly prolonged survival in breast cancer-bearing mice. Notably, no apparent side effects of rVP1 were detected, as shown by normal complete blood count levels and serum biochemistry profiles, including AST, ALT, BUN, and creatine. This study demonstrates that rVP1 suppresses the migration, invasion, and metastasis of breast cancer cells via binding to β1 integrin receptor and down-regulation of AP-2α and HER-2 expression. The effectiveness of rVP1 on inhibiting migration/metastasis of breast cancer and HER-2 expression suggests that it may be suitable for serving as potential therapeutics for metastatic breast cancer particularly HER-2-overexpressing cancer.

KW - Breast cancer

KW - HER-2

KW - Metastasis

KW - Migration

KW - rVP1

UR - http://www.scopus.com/inward/record.url?scp=84867882200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867882200&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2238-7

DO - 10.1007/s10549-012-2238-7

M3 - Article

VL - 136

SP - 89

EP - 105

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -